Literature DB >> 11708918

Design and pharmacological activity of phosphinic acid based NAALADase inhibitors.

P F Jackson1, K L Tays, K M Maclin, Y S Ko, W Li, D Vitharana, T Tsukamoto, D Stoermer, X C Lu, K Wozniak, B S Slusher.   

Abstract

A novel series of phosphinic acid based inhibitors of the neuropeptidase NAALADase are described in this work. This series of compounds is the most potent series of inhibitors of the enzyme described to date. In addition, we have shown that these compounds are protective in animal models of neurodegeneration. Compound 34 significantly prevented neurodegeneration in a middle cerebral artery occlusion model of cerebral ischemia. In addition, in the chronic constrictive model of neuropathic pain, compound 34 significantly attenuated the hypersensitivity observed with saline-treated animals. These data suggest that NAALADase inhibition may provide a new approach for the treatment of both neurodegenerative disorders and peripheral neuropathies.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11708918     DOI: 10.1021/jm0001774

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  27 in total

1.  A remote arene-binding site on prostate specific membrane antigen revealed by antibody-recruiting small molecules.

Authors:  Andrew X Zhang; Ryan P Murelli; Cyril Barinka; Julien Michel; Alexandra Cocleaza; William L Jorgensen; Jacek Lubkowski; David A Spiegel
Journal:  J Am Chem Soc       Date:  2010-09-15       Impact factor: 15.419

2.  [(18)F]Fluorobenzoyllysinepentanedioic Acid Carbamates: New Scaffolds for Positron Emission Tomography (PET) Imaging of Prostate-Specific Membrane Antigen (PSMA).

Authors:  Xing Yang; Ronnie C Mease; Mrudula Pullambhatla; Ala Lisok; Ying Chen; Catherine A Foss; Yuchuan Wang; Hassan Shallal; Hannah Edelman; Adam T Hoye; Giorgio Attardo; Sridhar Nimmagadda; Martin G Pomper
Journal:  J Med Chem       Date:  2015-12-16       Impact factor: 7.446

3.  The central nervous system effects, pharmacokinetics and safety of the NAALADase-inhibitor GPI 5693.

Authors:  J P van der Post; S J de Visser; M L de Kam; M Woelfler; D C Hilt; J Vornov; E S Burak; E Bortey; B S Slusher; T Limsakun; A F Cohen; J M A van Gerven
Journal:  Br J Clin Pharmacol       Date:  2005-08       Impact factor: 4.335

4.  Design and synthesis of a siderophore conjugate as a potent PSMA inhibitor and potential diagnostic agent for prostate cancer.

Authors:  Pingyu Ding; Paul Helquist; Marvin J Miller
Journal:  Bioorg Med Chem       Date:  2007-11-17       Impact factor: 3.641

Review 5.  Critical appraisal of neuroprotection trials in head injury: what have we learned?

Authors:  Christos M Tolias; M Ross Bullock
Journal:  NeuroRx       Date:  2004-01

Review 6.  Glutamate carboxypeptidase II in diagnosis and treatment of neurologic disorders and prostate cancer.

Authors:  C Bařinka; C Rojas; B Slusher; M Pomper
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

7.  A stereoselective synthesis of phosphinic acid phosphapeptides corresponding to glutamyl-gamma-glutamate and incorporation into potent inhibitors of folylpoly-gamma-glutamyl synthetase.

Authors:  David M Bartley; James K Coward
Journal:  J Org Chem       Date:  2005-08-19       Impact factor: 4.354

8.  Interactions between human glutamate carboxypeptidase II and urea-based inhibitors: structural characterization.

Authors:  Cyril Barinka; Youngjoo Byun; Crystal L Dusich; Sangeeta R Banerjee; Ying Chen; Mark Castanares; Alan P Kozikowski; Ronnie C Mease; Martin G Pomper; Jacek Lubkowski
Journal:  J Med Chem       Date:  2008-12-25       Impact factor: 7.446

9.  Pharmacokinetics and pharmacodynamics of the glutamate carboxypeptidase II inhibitor 2-MPPA show prolonged alleviation of neuropathic pain through an indirect mechanism.

Authors:  James J Vornov; Krystyna M Wozniak; Ying Wu; Camilo Rojas; Rana Rais; Barbara S Slusher
Journal:  J Pharmacol Exp Ther       Date:  2013-06-17       Impact factor: 4.030

10.  Structural basis of interactions between human glutamate carboxypeptidase II and its substrate analogs.

Authors:  Cyril Barinka; Klara Hlouchova; Miroslava Rovenska; Pavel Majer; Miroslawa Dauter; Niyada Hin; Yao-Sen Ko; Takashi Tsukamoto; Barbara S Slusher; Jan Konvalinka; Jacek Lubkowski
Journal:  J Mol Biol       Date:  2008-01-05       Impact factor: 5.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.